INTRODUCTION {#sec1-1}
============

Venous thromboembolism (VTE) is a common medical problem with a reported annual incidence of 1--2 new cases per 1000 populations in Europe and North America.\[[@ref1][@ref2][@ref3]\] Deep venous thrombosis (DVT) and pulmonary embolism (PE) are its two major subtypes. VTE is associated with a long-term morbidity and mortality with an estimated cumulative incidence of recurrence of 10% at 1 year and 30% at 5 years after the withdrawal of anticoagulation therapy.\[[@ref4]\] Several medical comorbidities, such as hospitalization, surgery, cancer, aging, thrombophilic state, and use of certain medications are the well-established risk factors.\[[@ref5][@ref6]\]

Several immune-mediated diseases, such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory myopathy, systemic sclerosis, and psoriasis have been increasingly recognized as predisposing factors for VTE.\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]\] Even though the mechanistic link between these disorders and VTE is not fully understood, several studies have suggested that chronic inflammation might be the major player for the increased VTE tendency.\[[@ref13][@ref14]\]

Ankylosing spondylitis (AS), one of the most common subtype of seronegative spondyloarthritis, is a chronic systemic arthritis characterized by enthesitis and axial joint involvement. AS typically affects young males with the peak incidence between 20 and 30 years old and male-to-female ratio of 3--1.\[[@ref15][@ref16]\] Nonmechanical back pain and progressive stiffness of the spine are the hallmarks of the disease through the involvement of peripheral joints can be seen as well. Extra-articular manifestations, such as uveitis, could be seen in about one-fourth of patients with AS.\[[@ref17]\]

In light of the higher inflammatory burden, patients with AS might be at an increased risk of venous thrombosis as seen in other autoimmune disorders. In fact, a recent meta-analysis has demonstrated that patients with AS have a higher risk of arterial thrombosis (i.e., coronary artery disease).\[[@ref18]\] Nevertheless, the epidemiological data on VTE risk in this group of the patient is limited. Therefore, to further investigate this possible association, we conducted a systematic review and meta-analysis of population-based studies that compared the VTE risk in patients with AS versus non-AS participants.

METHODS {#sec1-2}
=======

Search strategy {#sec2-1}
---------------

Two investigators (PU and NS) independently searched published studies indexed in MEDLINE and EMBASE from inception to March 2015 using the search terms described in the supplementary material without any language restriction. References of selected articles were also manually searched \[Supplementary Table 1\].

###### 

Click here for additional data file.

Inclusion criteria {#sec2-2}
------------------

The studies were eligible for this meta-analysis if they met these inclusion criteria: (1) Cohort (either prospective or retrospective) or case--control study published as original study to evaluate the association between AS and risk of VTE, (2) odds ratios, relative risk, hazard ratio, and standardized incidence ratio with 95% confidence intervals (CIs) or sufficient raw data to calculate these ratios were provided, and (3) participants without AS and participants without VTE were used as the reference group for cohort study and case--control study, respectively.

Study eligibility was independently evaluated by the two investigators noted above. The quality of each study was also independently appraised, using the Newcastle--Ottawa quality scale.\[[@ref19]\] This scale assessed each study in three domains including (1) the appropriateness of the selection of the participants, (2) the comparability between the study groups and, (3) the ascertainment of the exposure for case--control study and the outcome of interest for the cohort study. The review process was overseen the third investigator (WK) who resolved any different decisions between the first two investigators.

Data extraction {#sec2-3}
---------------

A standardized data collection form were used to extract the following information: Title of the article, first author\'s last name, year of publication, year of study, country where the study was conducted, criteria used for the diagnosis of AS, definition of VTE, methods used to identify cases and controls, number of cases, number of controls, percentage of male and female, average age of participants, assessed confounders, and adjusted effect estimates with 95% CI. This data extraction was independently conducted by the two investigators. Any data discrepancy was jointly examined by all investigators by referring to the original studies.

Statistical analysis {#sec2-4}
--------------------

All statistical analyses were conducted using Review Manager 5.3 software (London, United Kingdom) from the Cochrane collaboration. Point estimates and their 95% CI were extracted from each study and were pooled together using the generic inverse variance method of DerSimonian and Laird.\[[@ref20]\] Random-effect model, rather than a fixed-effect model, was used given the high likelihood of between-study variance. Cochran\'s Q-test, which is complemented with the I^2^ statistic, was used to evaluate the statistical heterogeneity. This I^2^ statistic quantifies the proportion of the total variation across studies, that is, due to true heterogeneity rather than chance. A value of I^2^ of 0% to 25% represents insignificant heterogeneity, more than 25% but ≤50% represents low heterogeneity, more than 50% but ≤75% represents moderate heterogeneity, and more than 75% represents high heterogeneity.\[[@ref21]\]

RESULTS {#sec1-3}
=======

Our search strategy yielded 423 potentially relevant articles (73 articles from MEDLINE and 350 articles from EMBASE). After the exclusion of 70 duplicated articles, 353 of them underwent title and abstract review. Two-hundred and seventy articles were excluded since they were case report, letter to editor, review article or interventional study; while 51 articles were excluded since they were not conducted in patients with AS, leaving 32 articles for a full-length article review. Twenty of them were excluded since they did not report our outcome of interest (VTE) while nine articles were excluded since they were descriptive studies without a control group. Therefore, a total of three studies (two retrospective cohort studies and one case--control study) met our inclusion criteria and were included in the data analysis.\[[@ref22][@ref23][@ref24]\] [Figure 1](#F1){ref-type="fig"} outlines our literature review and selection process. The main characteristics and the quality assessment of the included studies are described in [Table 1](#T1){ref-type="table"}.

![Outline of our search methodology and study selection](LI-33-642-g001){#F1}

###### 

Main characteristics of included studies

![](LI-33-642-g002)

We found a statistically significantly elevated VTE risk among subjects with AS compared with non-AS controls with the risk ratio of 1.60 (95% CI: 1.05--2.44). The risk ratios from individual study varied from 1.16 to 1.93. The statistical heterogeneity was high with an I^2^ of 93%. [Figure 2](#F2){ref-type="fig"} demonstrates the forest plot of this meta-analysis.

![Funnel plot of all included studies](LI-33-642-g003){#F2}

Evaluation for publication bias {#sec2-5}
-------------------------------

Since only three primary studies were included in this meta-analysis, an evaluation for publication bias was not performed.

DISCUSSION {#sec1-4}
==========

Our meta-analysis demonstrated a significant association between AS and VTE with an overall 1.6-folds (95% CI, 1.05--2.44) increased risk compared with non-AS participants.

Why patients with AS are at a higher risk of VTE is a subject for debate but appears to be related to a higher inflammatory burden as seen in other autoimmune disorders.\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]\] Inflammatory cytokines, such as interleukin-6, interleukin-8, and tumor necrosis factor-alpha, have been demonstrated to promote the coagulation cascade, inhibit the anticoagulation pathway and impair the fibrinolytic process, resulting in a thrombophilic state.\[[@ref25][@ref26][@ref27]\] Furthermore, the oxidative stress from chronic inflammation is known to cause a deleterious effect on endothelial cells.\[[@ref26][@ref28]\] These thrombophilic state and endothelial dysfunction are two of the three Virchow\'s triad\[[@ref5]\] that could well serve as the fundamental pathophysiology of the increased clotting tendency.

Moreover, patients with AS, because of their arthritis and joint immobility, may be less active compared with healthy subjects, rendering them at a higher risk of venous flow stasis, another risk factor for clot formation in the Virchow\'s triad.

Even though our search methodology was vigorous and the primary studies included in this analysis were of high quality, we acknowledged that there were some limitations. Therefore, our results should be interpreted with caution. First, all of the included studies were medical registry-based study which was at risk of coding inaccuracy and incompleteness for both AS and VTE. In fact, the study by Zöller *et al*.\[[@ref24]\] was the only study that confirmed the accuracy of diagnosis of VTE by chart review, while the other two studies relied exclusively on the database\'s diagnostic codes. Second, statistical heterogeneity was high in this meta-analysis. We suspect that the difference in population, study design, and definition of VTE (the studies by Ramagopalan *et al*.\[[@ref22]\] and Johannesdottir *et al*.\[[@ref23]\] included both DVT and PE while the study by Zöller included only patients with PE) were responsible for this. Third, this is a meta-analysis of observational studies that can only illustrate an association but cannot establish causalty. Several potential confounders, such as smoking and medications, rather than the disease itself, might be accountable for the increased VTE risk. Furthermore, detection bias might also play a role as patients with AS may have more medical examinations and laboratory investigations just because of their chronic illness.\[[@ref29]\]

CONCLUSION {#sec1-5}
==========

Our meta-analysis demonstrated a statistically significant increased VTE risk among patients with AS. In light of high morbidity and mortality associated with VTE, our study suggests that it would be prudent for physicians to carefully monitor patients with AS for VTE, especially those with other conventional risk factors.
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